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1504Background: Testosterone deﬁciency (TD) is an increasingly common problem with signiﬁcant health impli-
cations, but its diagnosis and management can be challenging.
Aim: To review the available literature on TD and provide evidence-based statements for UK clinical practice.
Methods: Evidence was derived from Medline, EMBASE, and Cochrane searches on hypogonadism, testos-
terone (T) therapy, and cardiovascular safety from May 2005 to May 2015. Further searches continued until
May 2017.
Outcomes: To provide a guideline on diagnosing and managing TD, with levels of evidence and grades of
recommendation, based on a critical review of the literature and consensus of the British Society of Sexual
Medicine panel.
Results: 25 statements are provided, relating to 5 key areas: screening, diagnosis, initiating T therapy, beneﬁts
and risks of T therapy, and follow-up. 7 statements are supported by level 1, 8 by level 2, 5 by level 3, and 5 by
level 4 evidence.
Clinical Implications: To help guide UK practitioners on effectively diagnosing and managing primary and age-
related TD.
Strengths and Limitations: A large amount of literature was carefully sourced and reviewed, presenting the
best evidence available at the time. However, some statements provided are based on poor-quality evidence. This
is a rapidly evolving area of research and recommendations are subject to change. Guidelines can never replace
clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions and
take personal values and preferences and individual circumstances into account. Many issues remain contro-
versial, but in the meantime, clinicians need to manage patient needs and clinical expectations armed with the
best clinical evidence and the multidisciplinary expert opinion available.
Conclusion: Improving the diagnosis and management of TD in adult men should provide somatic, sexual, and
psychological beneﬁts and subsequent improvements in quality of life. Hackett G, Kirby M, Edwards D, et al.
British Society for Sexual Medicine Guidelines on Adult Testosterone Deﬁciency, With Statements for UK
Practice. J Sex Med 2017;14:1504e1523.
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BSSM Guidelines on Adult Testosterone Deﬁciency 1505PANEL COMPOSITION
The British Society of Sexual Medicine (BSSM) panel consists
of a group of experts in urology, andrology, cardiology, psychi-
atry, and sexual medicine.SOURCES OF INFORMATION
The BSSM UK policy statements on testosterone deﬁciency
(TD), published in 2016,1 were based on evidence derived from
Medline, EMBASE, and Cochrane searches on hypogonadism,
testosterone (T) therapy, and cardiovascular (CV) safety from
May 2005 to May 2015, which yielded 1,714 articles, including
52 clinical trials and 32 placebo-controlled randomized
controlled trials (RCTs). Further searches continued until May
2017. Levels of evidence (LoEs) and grades of recommendation
were based on the Oxford Criteria for Evidence-Based
Medicine.2INTRODUCTION
T is the principal androgen in men. It is essential for the
development and maintenance of secondary male characteristics.3
When T levels decrease, patients can experience physical and
psychological effects, which can compromise their general well-
being, sexuality, and fertility.4,5
These statements have been developed for UK practice and
aim to address the widespread media and scientiﬁc concerns over
the appropriate treatment of TD with T therapy.
They apply to adult men only. Women are not included,
because there is currently no consensus for using T in women
and the T products available are not licensed for use in women.DEFINITION
TD is a well-established and signiﬁcant medical condition.1 It
is deﬁned as a clinical and biochemical syndrome associated with
advancing age and comorbidities (LoE ¼ 2, Grade ¼ B)6 and is
characterized by a deﬁciency in serum androgen levels (with or
without decreased genomic sensitivity to androgens1) and rele-
vant signs and symptoms.6,7
TD can adversely affect multiple organ systems and result in
signiﬁcant decreases in quality of life, including changes in sexual
function4,6,7 (LoE ¼ 2, Grade ¼ B).6EPIDEMIOLOGY
Estimates regarding the prevalence of TD vary widely. The
European Male Aging Study (EMAS) evaluated more than 3,000
men 40 to 79 years old according to biochemistry and symp-
toms. Results showed an overall prevalence of 2.1% in men 40 to
79 years old and rates of 0.1% in men 40 to 49 years old, 0.6%
in men 50 to 59 years old, 3.2% in men 60 to 69 years old, and
5.1% in men 70 to 79 years old (in which the syndrome of TDJ Sex Med 2017;14:1504e1523included 3 sexual symptoms associated with a total T [TT]
level < 11 nmol/L and a free T [FT] level < 220 pmol/L
[<0.22 nmol/L]).8 However, 75% of men maintained normal
T levels into old age, suggesting that TD is not merely a function
of aging. The prevalence of secondary TD was 11.8%, with 2%
having primary TD and 9.5% having compensated (subclinical)
TD, worthy of observation but not treatment with T.9
TD is more common in older men and those with obesity,
comorbidities, and poor health status.4BASIC PHYSIOLOGY
In eugonadal men, the regulation of T production is
controlled by the hypothalamic-pituitary-gonadal axis.3 In the
brain, the hypothalamus secretes gonadotropin-releasing hor-
mone, which stimulates the anterior pituitary gland to produce
follicle-stimulating hormone (FSH) and luteinizing hormone
(LH). In the testes, LH stimulates the Leydig cells to produce T,
and FSH stimulates the seminiferous tubules for sperm matu-
ration. Through a negative feedback mechanism, T inhibits
gonadotropin-releasing hormone and LH secretion, and the
hormone inhibin B, secreted by Sertoli cells, inhibits the release
of FSH.3,10
Androgen receptors (ARs) are present in many body tissues.
They allow the body to respond appropriately to T by attaching
(binding) to it. The resulting AR complex binds to DNA,
regulating the activity of androgen-responsive genes. The AR
gene contains a DNA segment known as CAG, which is repeated
multiple times. In most people, the number of CAG repeats
ranges from less than 10 to approximately 36.11 The length of
these repeats in the AR gene can inﬂuence androgen sensitivity,12
androgen action,13 and androgenic phenotypical effects, even in
the presence of normal T levels.14
T has multiple effects on the body. In the brain, it stimulates
libido and aggression and aids cognition, memory, and feelings.
In the kidneys, it promotes erythropoiesis. In the skin, it sup-
ports collagen production and stimulates hair growth and sebum
production. In the heart, it affects cardiac output and coronary
and peripheral blood ﬂow, decreases the corrected QT interval,
and decreases reperfusion injury. T also affects muscle mass and
strength, bone growth, density and erythropoiesis, growth of the
sex organs, spermatogenesis, and erectile function.1,15e18ETIOLOGY
TD occurs when the body cannot produce sufﬁcient T to
function normally. This can result from disruption of at least 1
level of the hypothalamic-pituitary-gonadal axis (LoE ¼ 1,
Grade ¼ A)6:
 Testes (primary TD, Figure 1)
 Hypothalamus and pituitary gland (secondary TD)
 Hypothalamus,19,20 pituitary, and testes (combined primary
and secondary TD; adapted from Grossman and Matsumoto19)
Figure 1. Primary hypogonadism. FSH ¼ follicle-stimulating hor-
mone; LH ¼ luteinizing hormone. Figure 1 is available in color at
www.jsm.jsexmed.org.
Figure 2. Secondary hypogonadism. FSH ¼ follicle-stimulating
hormone; LH ¼ luteinizing hormone. Figure 2 is available in color
at www.jsm.jsexmed.org.
1506 Hackett et alSecondary TD is the most common form.9,21 The term
“functional” (late-onset, age-related, or adult-onset) TD has
recently been introduced to describe androgen-deﬁciencyelike
features and low T levels in men older than 50 years associated
with conditions such as obesity and metabolic syndrome in the
absence of intrinsic, structural hypothalamic-pituitary-testicular
axis pathology and speciﬁc pathologic conditions suppressing
the hypothalamic-pituitary-testicular axis (eg, microprolactinoma
or endogenous Cushing syndrome19; Figure 2 presents other
causes of secondary TD). However, the BSSM is concerned that
that this deﬁnition might lead to men with potentially important
comorbid conditions going untreated.
Combined primary and secondary TD, sometimes known as
mixed TD, is associated with low T levels, impaired spermato-
genesis, and variable FSH and LH levels, depending on whether
primary or secondary testicular failure predominates.22 Com-
bined primary and secondary TD occurs with certain conditions
such as sickle cell disease, hemochromatosis, thalassemia, and
mutations in the DAX-1 gene and with glucocorticoid treatment
and alcoholism.22e24
Compensated TD occurs when men have normal levels of T
but higher gonadotropin levels. Characterized by increased LH
levels and older age, compensated TD has been proposed as a
genuine clinical subgroup of late-onset hypogonadism, from
which some men could eventually progress to overt primary
TD.9 Further studies are required to investigate the long-term
impact of compensated TD.
TD also can result if the action of T is impaired because of
decreased bioavailability of the hormone (resulting from variations in
sex hormone binding globulin [SHBG])6 or because of AR changes
that can affect androgen activity6,25 (LoE ¼ 2, Grade¼ A).6
Certain medications can suppress T levels, including oral
glucocorticoids, opioids, and antipsychotics26e29 (Table 1).
The clinical manifestations of TD result from decreased serum
androgen concentrations or activity, with or without an identi-
ﬁed underlying cause (LoE ¼ 1, Grade ¼ A).6CLINICAL DIAGNOSIS OF TD
The diagnosis of symptomatic TD requires the presence of
characteristic signs and symptoms (Level ¼ 2, Grade ¼ A)
plus decreased serum concentrations of TT or FT (LoE ¼ 2,
Grade ¼ A).26
The assessment of gonadotropins is required to determine the
origin of the TD (see section on Laboratory Diagnosis).SIGNS, SYMPTOMS, AND COMORBIDITIES
TD has well established symptoms (Table 2).1 The 4th In-
ternational Consultation for Sexual Medicine (ICSM)6 made the
following recommendations for the clinical diagnosis of TD
based on the following signs and symptoms:
 Sexual dysfunction, especially low sexual desire, decreased
morning and night-time erections, and erectile dysfunction
(ED) are prominent, commonly presenting symptoms partic-
ularly suggestive of TD when associated with each other
(LoE ¼ 1, Grade ¼ A).6
 Less speciﬁc symptoms such as fatigue, sleep disturbance, loss
of physical strength, decreased energy and motivation, and
depressed mood are often present (LoE ¼ 1, Grade ¼ B).6
 Visceral obesity and decreases in muscle mass and bone min-
eral density are commonly observed (LoE ¼ 1, Grade ¼ A).6
 Hot ﬂushes and changes in cognition and memory can be
associated with TD (LoE ¼ 3, Grade ¼ C).6
 On physical examination, features suggestive of TD include
decreased body hair, decreased testicular size, and gynecomas-
tia, but these are not always present (LoE ¼ 1, Grade ¼ B).6
Fine wrinkling of the skin, especially around the mouth, also
can be apparent.
Many signs and symptoms of TD are multifactorial in origin
and associated with various lifestyle and psychological factors
and with normal aging, so they can be found in men with normal
T levels.4,34J Sex Med 2017;14:1504e1523
Table 1. Clinical signs and symptoms suggestive of TD*,1,4,6e8,30,31
Sexual Physical
Delayed puberty Decreased body hair
Small testes Gynecomastia
Infertility Decreased muscle mass and strength
Decreased sexual desire and activity Hot ﬂushes or sweats
Decreased frequency of sexual thoughts Sleep disturbances
Erectile dysfunction Fatigue
Delayed ejaculation Osteoporosis, height loss, low trauma fractures
Decreased volume of ejaculate
Decreased or absent morning or night-time erections
Cardiometabolic Psychological
Increased BMI or obesity Changes in mood (eg, anger, irritability, sadness, depression)
Visceral obesity Decreased well-being or poor self-rated health
Metabolic syndrome Decreased cognitive function (including impaired concentration,
verbal memory, and spatial performance)
Insulin resistance and T2DM
BMI ¼ body mass index; T2DM ¼ type 2 diabetes mellitus.
*TD is often associated with increased waist circumference, obesity, metabolic syndrome, and impaired health status.1 In a primary care population of men at
least 45 years, the reported odds ratios for TD with comorbid conditions were 2.38 for obesity, 2.09 for T2DM, 1.84 for hypertension, 1.47 for dyslipidemia,
1.40 for chronic obstructive pulmonary disease, and 1.20 for lower urinary tract symptoms related to benign prostatic hyperplasia.32 Signiﬁcant TD is
associated with an increased risk of chronic anemia and osteoporosis.1 Table 2 presents a list of the conditions associated with an increased prevalence of TD.
Adapted from Hackett et al,1 Dohle et al,4 and Khera et al.6
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more than 80% of men maintain normal T levels into old
age.9 The age-related increase in SHBG does cause a decrease in
FT and bioavailable T, but the increased rates of TD seen in
older men are primarily related to an increased prevalence of
obesity, type 2 diabetes mellitus (T2DM), and chronic illness.36
The signs and symptoms of TD vary depending on age at
onset, duration, and severity.1,4 Although the prevalence of TD
increases with advancing age, it can occur in adult men of any age
(LoE ¼ 1, Grade ¼ B).6 The more signs and symptoms a man
has, the greater the probability that he has genuine TD.26,37
The prevalence of hypogonadal symptoms increases when TT
levels decrease below 12.1 nmol/L26,37 (LoE ¼ 2b, Grade ¼ A).26
However, they also are seen at higher levels. A cross-sectional
cohort study investigating the structure of complaints in 434Table 2. Factors associated with an increased prevalence of TD4,6,22,
Andrologic and
endocrinologic
Metabolic diseases
associated with
insulin resistance Cardiovascular diseases
Delayed puberty Obesity Hypertension
Cryptorchidism Metabolic syndrome Coronary artery disease
Pituitary disease Type 2 diabetes Cerebrovascular disease
Infertility Chronic heart failure
Varicocele Atrial ﬁbrillation
Adapted from Khera et al.6
J Sex Med 2017;14:1504e1523hypogonadal men 50 to 86 years old reported loss of erections at a
TT level of approximately 8 nmol/L, diabetes and depression at
10 nmol/L, obesity at 12 nmol/L, and decreased vigor at
15 nmol/L. The investigators found no evidence for a uniform
structure of T concentrations and complaints and concluded that
in aging men psychosomatic complaints and metabolic risk relate
to T in a symptom-speciﬁc manner.37RATIONALE FOR T THERAPY
Because many adult men with TD are sick and/or obese,
weight loss if overweight, lifestyle modiﬁcation, and optimal
management of comorbidities are important ﬁrst steps.4,38,39
However, a 4.3-year follow-up from the EMAS40 found that
biochemical reversal of secondary hypogonadism was not26,33
Other chronic diseases Pharmacologic
Chronic obstructive pulmonary
disease
Oral glucocorticoid treatment
Obstructive sleep apnea Regular opioid use
End-stage renal disease Antipsychotic medications
Cirrhosis Androgen deprivation therapy
Osteoporosis Methadone maintenance therapy
Rheumatoid arthritis Antiretroviral therapy
HIV Chemotherapy þ radiation
cancer Anticonvulsant therapy
1508 Hackett et alassociated with an improvement in symptoms. In addition, an
RCT of obese hypogonadal men treated with severe weight loss
and long-acting T undecanoate (TU) injections or placebo for 12
months found that although decreased weight and body mass
index (BMI) were achieved in the 2 groups, only the TU group
preserved lean muscle and achieved symptomatic beneﬁt.41,42
Therefore, we believe that current evidence does not support
the recommendation for lifestyle intervention alone as ﬁrst-line
therapy. Patients with low T present with distressing symp-
toms and therapy should be relevant to the effective relief of
those symptoms. Therefore, we endorse lifestyle modiﬁcation in
conjunction with T therapy in men with symptomatic TD
(LoE ¼ 2, Grade ¼ A).
T therapy is indicated for men with symptoms of TD sup-
ported by low biochemical levels. Because the 3 most common
symptoms of deﬁciency are ED, loss of early morning erections,
and low sexual desire, most candidates for T therapy present with
sexual dysfunction and a desire for treatment. The increasing
realization that ED is a strong marker for coronary heart disease
risk and recent recommendations on obesity and diabetes by the
American Association of Clinical Endocrinologists and the
American College of Endocrinology43,44 are likely to increase the
number of men detected by routine screening. Against this
recognition of the importance of T in cardiometabolic disease, it
is inevitable that the past 20 years has seen a large increase in
men being treated.45,46
In men, multiple symptoms such as loss of vitality, tiredness,
decreased strength, and tiredness also might demand attention.
In men with no other comorbidities, T therapy alone might
reverse the symptoms, but where other comorbidities exist,
ED-speciﬁc therapy (usually a phosphodiesterase type 5 inhibitor
[PDE5i]) will often be required. Studies have suggested that the
best responses in sexual symptoms are seen with baseline levels
below 8 nmol/L, that sexual desire improves by 6 weeks, but that
ED improvement could take longer. Beneﬁts in loss of fat mass
and increase of lean muscle mass can take at least 12 months.
Longer-term studies have suggested that symptoms improve
progressively over many years. Because most men will only
receive 1 trial of T therapy in their lifetime, we recommend a
minimum of 6 months, assuming effective levels are achieved. At
that point, continuation should be discussed once the patient has
received sufﬁcient accurate information for an informed decision.
Men whose T therapy has failed despite multiple doses (>8)
of a PDE5i can frequently be salvaged by correcting a TT level
lower than 12 nmol/L, although 1 trial showed signiﬁcance only
at levels below 10.4 nmol/L.47 T has been shown to upregulate
PDE5 and most trials of oral therapy have excluded men with
untreated TD. Failure of oral therapy in these men also could be
related to previously undetected low desire or ejaculatory or
orgasmic dysfunction or dislike of on-demand therapy by the
couple. T therapy could address these issues.48 With the avail-
ability of generic PDE5is, avoiding the progression to expensivesecond- and third-line therapies will become increasingly cost
effective.EVIDENCE FOR T THERAPY IN MEN WITH TD
In a retrospective study of men with TD, T therapy was
associated with an average decrease in American Urological
Association symptom index and International Prostate Symptom
Score of 7.42 in those with severe lower urinary tract symp-
toms (LUTS) at baseline.49 T therapy also has been associated
with an improvement in depression scores in RCTs.50
In the TIMES218 and BLAST51 studies, which recruited pa-
tients with T2DM and/or metabolic syndrome, T therapy was
associated with small beneﬁts in lipid metabolism, but blood
pressure was unaffected. T therapy appeared to attenuate insulin
resistance most markedly in patients with poorly controlled
T2DM. These beneﬁts were ampliﬁed when combined with
lifestyle modiﬁcation.51
A long-term registry study lasting longer than 5 years showed
progressive weight loss with T therapy, decreases in waist
circumference and BMI, total and low-density lipoprotein
cholesterol, triglycerides, systolic and diastolic blood pressure,
blood glucose, and C-reactive protein, and an increase in high-
density lipoprotein cholesterol.52,53
A more recent RCT from Australia evaluated severely obese
men with hypogonadism in a double-blinded RCT involving
long-acting TU or placebo plus intense dieting in the ﬁrst 10
weeks. At 12 months, there was no signiﬁcant difference in
weight loss, BMI, and waist circumference, but the men on TU
preserved all their lean muscle, whereas men on the diet alone
lost an additional 3.5 kg of lean muscle compared with the TU
group. The active group also showed signiﬁcant loss of visceral
and appendicular fat plus increased grip strength.42
In a meta-analysis of 59 RCTs involving 5,078 subjects, T
therapy was not associated with any signiﬁcant changes in body
weight, BMI, or waist circumference, but it consistently
improved lean muscle and decreased fat mass.54
The Testosterone Trials were a set of 7 coordinated, double-
blinded, placebo-controlled trials conducted at 12 sites55
involving 790 men at least 65 years old with serum T concen-
trations lower than 275 ng/dL. Participants received T or placebo
gel for 1 year. Dosing was adjusted to maintain T concentrations
within the normal range for young men (19e40 years of age).
Efﬁcacy was assessed at baseline and then at 3, 6, 9, and 12
months.56
In men who participated in at least 1 of 3 the Testosterone
Trials (Sexual Function Trial, Physical Function Trial, and
Vitality Trial), T therapy was associated with signiﬁcant im-
provements in sexual desire, sexual activity, and erectile function
and modest improvements in 6-minute walking test, mood, and
depression.56J Sex Med 2017;14:1504e1523
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volumetric bone mineral density and estimated bone strength.
These changes were greater in trabecular than in peripheral bone
and in the spine than in the hip. Larger and longer trials are
required to determine whether this treatment also lowers fracture
risk.57 Earlier evidence had shown that T therapy consistently
improved bone mineral density in the lumbar spine but was not
associated with signiﬁcant improvements in hip scores.58
The Anaemia Trial55 found that T therapy signiﬁcantly
increased hemoglobin levels in men with anemia from unex-
plained or known causes,59 whereas the Cognitive Function
Trial55 found no effect on memory or other cognitive function.60
Several meta-analyses of RCTs, notably by Corona et al61 in
2017, concluded that T therapy in men with TD signiﬁcantly
improves sexual desire and erectile function (particularly in men
with T levels < 8 nmol/L) and increases sexual activity, satis-
faction, and orgasm.1
A limitation of some of the aforementioned RCTs is that they
were of relatively short duration, usually 3 to 12 months. The
evidence strongly suggests that trials of T therapy should last at
least 6 months.1,51
TD is commonly associated with decreased fertility.4 In
younger men, T therapy lowers LH and FSH levels and
frequently causes infertility after 6 to 12 months; but this is
reversible in 60% to 70% of men within 9 to 12 months.62TD AND INCREASED CV AND ALL-CAUSE
MORTALITY
Numerous long-term studies and various reviews and meta-
analyses have provided evidence to support the association be-
tween TD and increased CV and all-cause mortality,1,63e68
although evidence for a pathogenic link is lacking.1,69
A systematic review and meta-analysis evaluating the associa-
tion between endogenous T and mortality concluded that low
levels of endogenous T were associated with an increased risk of
all-cause and CV death in community-based studies of men, with
a decrease of 2.1 SD in TT being associated with a 25% increase
in mortality. However, most of these studies had issues with
cohort selection and choice.63
2 systematic reviews and meta-analyses evaluating the associ-
ation between endogenous T and all-cause63 and CV disease
(CVD)63,64 mortality reported a protective effect of increased
TT. Research examining the data from 1,954 subjects using
several statistical models found that even after strict adjustment
for comorbidities, there was a consistent link between T level and
mortality risk throughout, without proving causation.65
In a prospective study involving 581 men with T2DM, pa-
tients were followed for a mean of 5.81 years. Low T was deﬁned
as a TT level lower than 10.4 nmol/L. 51 men received T
therapy for at least 2 years. Mortality rates were 20% in the low
T group vs 9.1% in the normal T group, independent ofJ Sex Med 2017;14:1504e1523comorbidities and therapies, and 9.4% in those with TD in the
treated group.66
In a 10-year Australian study involving 3,690 older men, TT
and FT levels in the normal range were associated with lower all-
cause and CV mortality. This was the ﬁrst evidence to suggest
that low and high levels are associated with all-cause mortality
and that higher levels of dihydrotestosterone lower CV risk.67
A Swedish study involving 1,109 subjects at least 40 years old,
with a mean follow up of 14.1 years, suggested a strong
association between low baseline T and incident myocardial
infarction (MI).68
Although these studies demonstrated a consistent association
between low T and CVD incidence and mortality, this did not
prove a pathogenic link.1,69 However, the conclusions from a
review on T and mortality were that low T could be a “marker”
of illness.70
6 studies, mostly involving small samples, found that low TT
and FT were associated with coronary artery disease (CAD), but
4 found no association. 4 studies found inverse associations be-
tween low TT and FT and CAD severity.69,71 However, such
studies do not determine whether low TT or FT is a cause or a
consequence of CAD.69POSSIBLE INCREASED CV RISK WITH T THERAPY
Although it has been proposed that serum dihydrotestosterone
can increase the risk of CVD through mechanisms involving
inﬂammation, coagulation, and vasoreactivity,72,73 the results of
studies investigating this association have been conﬂicting.
Concerns regarding T therapy in elderly men stem initially
from the premature discontinuation of the Testosterone in
Older Men (TOM) trial,74 which involved 209 frail, elderly
men with a mean age of 74 years. This study was not powered to
detect differences in CV events, but it was stopped early because
of 23 CV-related events (2 deaths) in the 106 men in the T
group vs 5 in the placebo group, despite positive results in study
end points. The primary limitation of interpreting CV risk from
this trial is that most adverse CV events were of questionable
signiﬁcance (eg, palpitations and non-speciﬁc electrocardio-
graphic changes) and were not systematically queried. It also
involved treatment initiation with topical T gel 100 mg (twice
the recommended starting dose) and then rapid escalation up to
150 mg/day (above the manufacturer’s recommended dose), and
many of the events were reported with inadequate validation
and mainly occurred in those subjects receiving the higher
doses.1,75 Similar dosing regimens used several years later in 790
men in the Testosterone Trials failed to reproduce these ﬁnd-
ings, and in the 12-month study, there were 3 deaths reported
on T and 7 on placebo.56
A retrospective American study76 involved 8,709 men with a
baseline TT level no higher than 10.4 nmol/L who were un-
dergoing angiography. During a mean follow-up of 840 days,
1510 Hackett et al681 of the 7,486 patients not receiving T therapy died, 420 had
MIs, and 486 had strokes. Of the 1,223 patients receiving T
therapy, 67 died, 23 had MIs, and 33 had strokes. Complex
statistical analysis using more than 50 covariates concluded there
was a greater risk in the T therapy group. However, there were
concerns regarding the exclusion of 1,132 patients who experi-
enced events because they were prescribed T therapy after the
event, when they should have been included in the untreated
group, increasing the events by 70%. When challenged, the in-
vestigators revised the number to 132, but admitted that 104
women had been mistakenly included in the results.1 There also
were no data conﬁrming a correct diagnosis of TD syndrome
before T therapy and none on compliance with therapy. Treated
patients had baseline T levels 1.2 nmol/L below that of the
untreated group and therefore would have been at increased risk,
especially if undertreated, a possibility conﬁrmed by the
investigators.
A study analyzing prescribing data in men treated with T
therapy, without records of blood results or symptoms, deﬁned
non-fatal coronary events as themajor end point, assessed in the 12
months before and 3 months after therapy.77 However, the ben-
eﬁts of T therapy take longer than this to appear and other studies
have excluded theﬁrst 3months treatment from analysis because of
the likelihood of events relating to the pre-existing condition.
Crucially, data on fatal CV events and all-cause mortality were not
collected, despite T therapy in other studies reporting a major
impact on mortality rather than event numbers. 12-month post-
treatment data were collected but not presented. Before treat-
ment, the event rates within the groups were strangely identical.
There was a small increase in non-fatal cardiac events inmen taking
T therapy, which was more marked in those with increased risk.
Overall, events were fewer than predicted from comparable
research. The lack ofmortality data demonstrates a failing to realize
that a treatment that decreasedmortality was likely to increase non-
fatal events. In addition, the study design was not prospective,
which casts doubts on the validity of retrospective assessment for
the 12-month pretreatment period. Although this study has been
widely quoted in public media, it is discredited by several design
ﬂaws and statistical analyses.1
In the Cardiovascular Trial set of the Testosterone Trials, 170
men were assessed by cardiac computed tomographic angiog-
raphy for baseline and 1-year plaque burden. Compared with
placebo, T therapy was associated with a signiﬁcantly greater
increase in non-calciﬁed plaque volume over 12 months. Un-
fortunately, there was a signiﬁcantly greater baseline plaque level
in the placebo group that resulted in multiple interventions
including stents and bypass grafting.78 However, the lack of
change in coronary calcium in this study raises questions as to the
reliability of the result of non-calciﬁed plaque. The investigators
reported no coronary events or signiﬁcant drug changes in either
cohort throughout the study.
A recent systematic review and meta-analysis evaluated
whether T therapy was associated with an increased risk ofserious CV events compared with other treatments or placebo. It
included 39 RCTs and 10 observational studies. The meta-
analysis used data from 30 RCTs. Compared with placebo, T
therapy was not associated with any signiﬁcant risk in MI, stroke,
or mortality. However, the strength of the evidence for the 3
outcomes was classed as low, because of the risk of bias in the
included RCTs and imprecision. These results reﬂect those of
several other systematic reviews and meta-analyses that have
yielded inconclusive ﬁndings, representing the many limitations
of the individual studies. Patient-level data could not be used,
many studies did not specify the reasons for study withdrawal,
and whether the adverse events were identiﬁed using prespeciﬁed
criteria for safety end points, potentially biasing the results, and
the impact of the pharmaceutical industry funding was not
explored. The results from the observational studies varied
greatly and thus were not pooled statistically. The strengths of
this study included rigorous and comprehensive screening of
several databases, the inclusion of trials and observational studies,
focusing on speciﬁc disaggregated CV end points of clinical in-
terests, the use of meta-analytic approaches suitable for sparse
data, evaluation of the stability of the results in several sensitivity
analyses, and, in contrast to previous studies, the provision of
strength-of-evidence ratings for the evidence. Until the results of
prospective trials become available, rigorously designed observa-
tional evidence will continue to expand the growing evidence
base on the risks and beneﬁts of T therapy and its optimal
clinical application.79STUDIES SUGGESTING DECREASED CV RISKWITH
T THERAPY
In a retrospective study involving 1,031 hypogonadal men,
372 of whom took T therapy, the cumulative mortality was 21%
in the untreated group vs 10% in the treated group. The greatest
effect was observed in younger men and those with T2DM.80
In a prospective study involving 581 men with T2DM, pa-
tients were followed for a mean of 5.81 years. Low T was deﬁned
as a TT level lower than 10.4 nmol/L. 51 men received T
therapy for at least 2 years. Mortality rates were 20% in the low
T group vs 9.1% in the normal T group, independent of
comorbidities and therapies, and 9.4% in those with TD in the
treated group.66
The 2 aforementioned studies were criticized for possible se-
lection bias, but their strengths were reliable pretreatment diag-
nosis and accurate reporting of medications.1,69,81
A real-life observational registry study82 assessed the long-term
effectiveness and safety of parenteral TU used for up to 10 years
in 656 men with a mean age of 60.7 years. It concluded that
long-term treatment was well tolerated, with excellent adherence.
Furthermore, mortality related to CVD was signiﬁcantly
decreased in the group taking T vs the untreated group.
A retrospective study followed 857 men with T2DM for 4
years after baseline T measurement. Patients were randomized toJ Sex Med 2017;14:1504e1523
BSSM Guidelines on Adult Testosterone Deﬁciency 1511long-acting TU or placebo. Results showed that low baseline TT
and FT levels were associated with increased all-cause mortality.
T therapy and the use of PDE5is were independently associated
with lower all-cause mortality, with the greatest beneﬁt from the
2 treatments being seen in older men.83,84
Sharma et al85 retrospectively evaluated 83,010 male veterans
with recorded low TT levels. Subjects were categorized into 3
groups: T therapy with resulting normalization of TT levels (group
1), T therapy without normalization of TT levels (group 2), and
no T therapy (group 3). All-cause mortality (hazard ratio ¼ 0.53,
95% CI ¼ 0.50e0.55), risk of MI (hazard ratio ¼ 0.82, 95%
CI ¼ 0.71e0.95), and stroke (hazard ratio ¼ 0.70, 95% CI ¼
0.51e0.96) were signiﬁcantly lower in group 1 vs 2 (n ¼ 25,701,
median age ¼ 66 years, mean follow-up ¼ 4.6 years).
A study comparing acute MI rates in 6,355 men receiving at
least 1 T injection compared with a matched placebo group over
8 years found no overall increase in events. In those at greatest
risk, there was a signiﬁcant decrease in events and mortality.
There was no increased risk from venous thromboembolism.86
In a virtual controlled study, researchers examined electronic
medical records from 1996 to 2011 to identify 5,695 men with a
low initial TT level, a subsequent T level, and up to 3 years of
follow-up. T levels were correlated with the use of T supple-
mentation. The primary outcomes were a composite of death,
non-fatal MI, and stroke (major adverse cardiac events) and
death alone. T supplementation in men with low T levels was
associated with a lower incidence of major adverse cardiac events
and death over 3 years compared with no or ineffective supple-
mentation. The results suggest that the positive impact of T
therapy was mainly on mortality as opposed to the number of
events, and the beneﬁts were associated with the achievement of
therapeutic levels of T. There was no suggestion of increased risk
with sustained higher serum levels.87
More recently, the same group reported a signiﬁcant decrease
in CV events in a cohort of hypogonadal men with angio-
graphically diagnosed CAD.88
In a study of 10,311 T-treated men compared with 28,029
controls, Wallis et al89 found a decrease in all-cause and CV
mortality with T therapy achieved and maintained in the normal
range, with an increase in mortality in the ﬁrst 6 months
compared with normal, most likely because of the impact of
underlying undertreated TD. This study also reported a 40%
decrease in new diagnoses of prostate cancer (pCa) in the treated
group compared with the control group.
Cheetham et al90 retrospectively reported on 8,808 T-treated
and 35,527 untreated men with low T and found a 33%
decrease in cardiac events associated with T therapy.
These studies present the most compelling evidence to date for
the safety of T therapy in patients, with a decrease in mortality in
clearly deﬁned TD treated to the therapeutic range, suggesting
that studies with negative outcomes usually included inadequate
diagnosis and little evidence of effective therapeutic levels orJ Sex Med 2017;14:1504e1523adequate follow-up and failed to exclude the possibility that
increased risk is related to TD and not its treatment.69
Registry studies have published data collected over 6 years of
follow-up, with no suggestion of increased mortality.91FINDINGS FROM META-ANALYSES
A meta-analysis of 27 placebo-controlled trials of T therapy
lasting longer than 12 weeks concluded that it could increase the
risk of CV-related events. However, most studies involved small
cohorts with a small number of events.92 The investigators were
criticized for their selection and inclusion of studies,1,93 and their
ﬁndings were heavily skewed1 by over-reliance on the TOM
study74 and the studies by Vigen et al76 and Finkle et al.77
Another meta-analysis, published the same year, concluded
that T therapy was not associated with increased risk, and in
certain cohorts there was evidence of fewer events, especially in
men with cardiometabolic disease.93
In response to these publications and US media publicity, the
Food and Drug Administration issued a request for more in-
formation on the safety of T from future studies,94 whereas a
bulletin from the European Medicines Agency expressed no
concerns.95T THERAPY AND RISK OF PCA
Concerns about T therapy and pCa date back to 1941, when
Huggins and Hodges96 reported that marked decreases in T by
castration or estrogen treatment caused metastatic cancer to regress,
but that administration of exogenous T caused pCa to grow.
The paradox of why lowering T causes pCa to regress, but
raising T fails to cause pCa to grow, can be explained by the
saturation model, which posits a ﬁnite ability of androgens to
stimulate pCa growth.97 The AR becomes saturated in human
prostate tissue at approximately 8 nmol/L in vivo,98,99 and there
appears to be no further appreciable growth with increasing
serum T concentrations beyond a saturation point of approxi-
mately 8 to 8.7 nmol/L.97 This explains why men with T below
the saturation point of approximately 8.7 nmol/L at baseline are
likely to see an increase in prostate-speciﬁc antigen (PSA) at
treatment initiation, whereas PSA is unlikely to increase in men
with T above this level.100
A meta-analysis of 19 randomized, placebo-controlled
T therapy studies, published in 2005, which included 651
men at least 45 years old with low or low to normal T level,
found no statistically signiﬁcant differences in pCa, PSA levels
higher than 4.0 ng/mL, or urinary symptom scores between
those receiving T therapy and those receiving placebo.101
A collaborative analysis of 18 prospective studies, comparing
3,886 men with incident pCa with 6,438 age-matched controls,
showed no association between T levels and pCa. There was no
difference in the relative risk of pCa between men with the
highest 20% of T levels and those with the lowest 20%.102
Recommendations—screening LoE Grade
Screen for TD in adult men with consistent
and multiple signs of TD
3 C
Screen all men presenting with ED, loss of
spontaneous erections, or low sexual desire
1 A
Screen for TD in all men with T2DM,
BMI > 30 kg/m2 or waist circumference
> 102 cm
2 A
Screen for TD in all men on long-term opiate,
antipsychotic, or anticonvulsant medication
2 B
1512 Hackett et alMore recently, the placebo arm of the REDUCE trial, which
investigated dutasteride for preventing pCa and included results
from 3,255 men who had prostate biopsy examinations at 2 and
4 years, showed no association between serum T or dihy-
drotestosterone and pCa risk. The risk of pCa was no greater in
men with high T levels than those with low T levels.103
Guidelines from the European Association of Urology
(EAU),4 the BSSM,5 the ICSM,6 the International Society of
Sexual Medicine (ISSM),7 the Endocrine Society (ES),22 and the
International Study of the Aging Male (ISSAM)26 conclude that
there is no compelling evidence that T therapy is associated with
an increased risk of pCa. The ISSAM26 stated that there is no
evidence that T therapy converts subclinical prostatic lesions into
clinically detectable pCa (LoE ¼ 2, Grade ¼ B), and the ICSM6
stated that there is no compelling evidence that T therapy in-
creases the risk of pCa or is associated with pCa progression
(LoE ¼ 1, Grade ¼ C).
Recent research has suggested that lower T levels are associated
with a risk of poorly differentiated cancers and greater risk of
positive biopsy results,104 and there is strong evidence linking
low T concentrations to aggressive high-grade pCa, higher rates
of positive biopsy results, biochemical recurrence, and disease
progression in men under active surveillance.105
However, estimates suggest that to detect a 30% difference in
pCa rates between T- and placebo-treated men, approximately
6,000 men 65 to 80 years old with low T levels would need to be
randomized to T or placebo treatment for an average of 5 years.
Because such an RCT would probably include relatively healthy
older men with unequivocally low T levels but without pCa or
PSA levels higher than 4 ng/mL, it would require screening of a
signiﬁcantly larger number of older men to enroll the required
number of eligible participants. Because it seems unlikely that a
study of this size will be funded, it will remain uncertain whether
long-term T therapy affects the incidence of clinically overt
pCa.106,107
Careful assessment of the prostate before starting T therapy
and regular monitoring for prostate disease once the patient is on
T therapy remain essential. Early increases in PSA after initiation
of T therapy could unmask an occult prostate carcinoma that was
undetected at baseline.
ROUTINE MEASUREMENT OF T
The EAU108 and BSSM5 guidelines on male sexual dysfunc-
tion recommend that all men with ED should have an initial
measurement of T as the minimal standard and that rechecking is
indicated in the event of poor response to PDE5is.
National Institute for Health and Care Excellence guidance109
recommends that men with T2DM should be asked about ED
annually and assessed, educated, and supported as necessary.
In 2016, the American Association of Clinical Endocrinolo-
gists and American College of Endocrinology guidelines on the
management of obesity110 recommended that all men with awaist circumference larger than 102 cm or BMI higher than
30 kg/m2 be assessed for TD by history, clinical examination,
and measurement of T. They recommended measurement of T
in all men with diabetes. They pointed out that weight loss and
lifestyle change should always form part of the management, but
that a signiﬁcant increase in T is not usually seen unless more
than 5% to 10% of weight loss is achieved. They also recom-
mended T measurement in men with chronic disease such as
HIV and chronic renal disease.
Screening for low T is not recommended in the absence of TD
symptoms in all other populations (including those with CVD,
chronic pulmonary diseases, cirrhosis, end-stage renal diseases,
rheumatoid arthritis, and cancer), because although such con-
ditions are potentially associated with an increased prevalence of
low T, there is a lack of evidence for beneﬁt of T therapy in
asymptomatic individuals (LoE ¼ 3, Grade ¼ B).6HISTORY TAKING AND QUESTIONNAIRES
History taking should include signs and symptoms suggestive
of TD (Table 1), pharmacologic treatment with corticosteroids
or opiates, abuse of drugs such as marijuana, alcohol, and
anabolic steroids, and previous treatment or use of T. It is
important to assess and exclude systemic illness, ongoing acute
disease, malabsorption, and malnutrition.4
Clinical assessment can be supported by the use of validated
questionnaires such as the Aging Male Symptoms Scale (available
at: http://www.issam.ch/AMS_English.pdf and http://www.
issam.ch/AMS_English_Evaluation.pdf) and the ANDROT-
EST111 to provide a quantitative baseline assessment of baseline
symptoms and evaluate the clinical response to treatment. We
endorse the use of validated questionnaires to demonstrate
changes in symptoms with T therapy.
Because the signs and symptoms can be non-speciﬁc,4 patients
at risk of or suspected of having TD should receive a thorough
physical and biochemical workup5,26 (LoE ¼ 2, Grade ¼ A).26PHYSICAL EXAMINATION
Physical examination in men with suspected TD should
include measurement of height, weight, BMI, and waist
circumference,22,26,112 assessment of the degree and distributionJ Sex Med 2017;14:1504e1523
Recommendations—diagnosis LoE Grade
Restrict diagnosis of TD to men with
persistent symptoms suggesting TD
and conﬁrmed low T
3 C
Measure fasting T levels in the morning
before 11 AM, acknowledging that, in normal life,
non-fasting levels could be up to 30% lower
2 A
Repeat TT assessment on 2 occasions by a
reliable method; in addition, measure FT in
men with levels close to the lower normal
range (8e12 nmol/L) or those with suspected
or known abnormal SHBG levels
1 A
Measure LH serum levels to differentiate primary
from secondary TD
2 A
Base decisions on therapy on published action
levels rather than laboratory reference ranges
4 B
BSSM Guidelines on Adult Testosterone Deﬁciency 1513of body hair (including facial and pubic), and examination for
the presence of acanthosis nigricans associated with insulin
resistance,26,113e116 presence and degree of breast enlargement,
appearance of the penis, presence of subcutaneous plaque,
testicular size and consistency, and scrotum size and abnormal-
ities.4,26 The prostate also should be examined by digital rectal
examination (DRE).4
LABORATORY DIAGNOSIS
Because the diurnal rhythmof serumTmeans levels are highest in
the early morning, T measurement before 11 AM is particularly
important for men younger than 40 years.6 Although diurnal vari-
ation is substantially blunted inoldermen,26 itmight still be evident,
even in the elderly, supporting the recommendation of restricting T
measurement to the morning hours for all age groups.117
Serum T should be measured from 7 to 11 AM (LoE ¼ 2a,
Grade ¼ A) on at least 2 occasions with a reliable method
(LoE ¼ 1, Grade ¼ A),26 preferably 4 weeks apart and, if
possible, not during an acute illness. Because T levels are inﬂu-
enced by insulin, glucose 75 g was shown to lower T by 25%.118
Although there is a lack of evidence supporting the necessity of
evaluating fasting T, the EAU recommended that T be measured
in the fasting state,4 which ﬁts conveniently into the routine blood
testing for dyslipidemia, hypertension, and diabetes. Until further
evidence is accumulated, we also believe that fasting testing is
appropriate for a ﬁrst test. Fasting levels were found to be up to
30% higher than non-fasting levels in volunteer and normal
population studies involving a 75-g glucose load.118,119We believe
it is doubtful whether these ﬁndings would be applicable to a
hypogonadal population inwhich diurnal variation inT is typically
absent. We recognize that most published RCTs involved fasting
levels.We recommend that clinicians should be aware that patients
do not routinely fast and therefore might have daily levels below
those detected by fasting measurement.
Assays of TT, performed by most laboratories in the everyday
clinical setting, are readily available and relatively inexepensive.6
Although widely recommended as the standard for research,
equilibrium dialysis is most widely used clinically, most notably
in the EMAS studies, in which the results of equilibrium dialysis
diagnosis were found to correlate well with isotope dilution gas
chromatographic mass spectrometry.120
Assays of FT based on analogue displacement immunoassays
produce unpredictable results and are not recommended. In obese
men, the free androgen index, calculated as TT/SHBG  100, is
used by some laboratories but we recommend the calculated FT
derived from SHBG and albumin through the equation of Ver-
meulen et al.121 An online FT calculator and downloadable app,
sponsored by the Primary Care Testosterone Advisory Group, can
be found at http://www.pctag.uk/testosterone-calculator/. The
ISSAM also provides an online FT calculator (available at: http://
www.issam.ch/freetesto.htm). The free androgen index is not as
reliable as FT or bioavailable T.122J Sex Med 2017;14:1504e1523It is important that clinicians familiarize themselves with their
local laboratories. TD is a diagnosis made from clinical symp-
toms and abnormal biochemistry. Clinicians need to appreciate
that “reference ranges” quoted by laboratories represent the
normal population and that the” action levels” recommended by
the BSSM refer to men with clinical symptoms of TD, just as
reference ranges on normal lipids are inappropriate for men with
T2DM and for secondary prevention in coronary heart disease.
Wide variations in laboratory practice for T testing in the United
Kingdom can lead to variations in patient care and potentially
result in some patients with TD not being identiﬁed. Improve-
ments in the standardization of T assays and the consistency of
reporting between laboratories are required.
When TT levels are close to the lower normal range (8e12
nmol/L), the FT level also should be checked4,5 (LoE ¼ 1,
Grade ¼ A).4 When TT levels are lower than 12 nmol/L, serum
LH and FSH levels also should be measured. When TT level is
borderline or low to normal, particularly in obese and older men,
SHBG levels also should be checked (LoE ¼ 2, Grade ¼ C).6
For known or suspected abnormal SHBG levels, FT also
should be measured (LoE ¼ 1, Grade ¼ A). LH levels should be
assessed to differentiate between primary and secondary TD
(LoE ¼ 2, Grade ¼ A).4 Serum prolactin levels should be
measured when LH and FSH levels are low. A very low TT level
(<5.2 nmol/L) and low LH and FSH levels are more likely to be
associated with hyperprolactinemia or when secondary TD from
a pituitary tumor or other pituitary disease is suspected.
For other investigations, in men with T levels lower than 5.2
nmol/L and increased prolactin levels or decreased LH and FSH
levels, pituitary magnetic resonance imaging should be per-
formed to exclude a pituitary adenoma.6,22
The EAU4 recommends screening for concomitant osteopo-
rosis in men older than 50 years with established TD (LoE ¼ 2,
Grade ¼ B).
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1514 Hackett et alTHRESHOLDS FOR T THERAPY
Regarding the thresholds for treatment intervention in
symptomatic men, BSSM1,5 and ISSM123 guidelines recommend
the following:
 TT level lower than 8 nmol/L or FT level lower than 180
pmol/L (<0.180 nmol/L; based on 2 separate levels from 8 to
11 AM) usually requires T therapy.1
 TT level higher than 12 nmol/L or FT level higher than 225
pmol/L (>0.225 nmol/L) does not require T therapy.1
 Levels from 8 to 12 nmol/L might require a trial of T therapy
for a minimum of 6 months based on symptoms (LoE ¼ 3,
Grade ¼ C).123
BSSM guidelines also state:
 A FT level lower than 225 pmol/L (0.225 nmol/L) provides
supportive evidence for T therapy in the presence of appro-
priate symptoms.124
Additional recommendations include:
 Increased LH levels and T levels below normal or in the lower
quartile range indicate testicular failure, so T therapy should be
considered.26,125
 Increased LH levels in men with normal T levels but symp-
toms of TD should be considered as having TD.26
 Recent data from the EMAS124 found that clinical
symptoms were more closely related to calculated FT
(LoE ¼ 2, Grade ¼ B).Ta
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Recommendations—initiating T therapy LoE Grade
Perform CV, prostate, breast, and hematologic
assessments before start of treatment
1a A
Offer T therapy to symptomatic men with
TD syndrome for treated localized low-risk
prostate cancer (Gleason score < 8, stages 1e2,
preoperative PSA level < 10 ng/mL, and not
starting before 1 y of follow-up) and without
evidence of active disease (based on measurable
PSA level, DRE result, and evidence of
metastatic disease)
3 B
Assess CV risk factors before commencing
T therapy and optimize secondary prevention
in men with established disease
1a AT THERAPY
There are many different T preparations available (Table 3),
which differ in their formulations, routes of administration,
dosage intervals, and safety proﬁles. Aromatizable T is recom-
mended for replacement therapy.26
Oral therapies are rarely used in the United Kingdom because
of the need for multiple dosing regimens and fears of hepato-
toxicity. The choice usually lies between the transdermal route
and long-acting TU. The features of each method should be
discussed with the patient. Based on current evidence, we can seeJ Sex Med 2017;14:1504e1523
Table 4. British Society for Sexual Medicine recommendations for UK practice with levels of evidence and grades of recommendation
LoE Grade
Recommendations—screening
Screen for TD in adult men with consistent and multiple signs of TD 3 C
Screen all men presenting with ED, loss of spontaneous erections, or low sexual desire 1 A
Screen for TD in all men with type 2 diabetes, BMI > 30 kg/m2, or waist circumference > 102 cm 2 A
Screen for TD in all men on long-term opiate, antipsychotic, or anticonvulsant medication 2 B
Recommendations—diagnosis
Restrict diagnosis of TD to men with persistent symptoms suggesting TD and conﬁrmed low T level 3 C
Measure fasting T levels in the morning before 11 AM, acknowledging that, in normal life, non-fasting levels
could be up to 30% lower
2 A
Repeat TTassessment on 2 occasions by a reliable method; in addition, measure free T in men with levels
close to lower normal range (8e12 nmol/L) or those with suspected or known abnormal SHBG level
1 A
Measure LH serum levels to differentiate primary from secondary TD 2 A
Base decisions on therapy on published action levels rather than laboratory reference ranges 4 B
Recommendations—initiating T therapy
Perform cardiovascular, prostate, breast, and hematologic assessments before start of treatment 1a A
Offer T therapy to symptomatic men with TD syndrome for treated localized low-risk prostate cancer
(Gleason score < 8, stages 1e2, preoperative PSA level < 10 ng/mL, and not starting before 1 y of
follow-up) and without evidence of active disease (based on measurable PSA level, DRE result, and
evidence of metastatic disease)
3 B
Assess cardiovascular risk factors before commencing T therapy and optimize secondary prevention in men
with established disease
1a A
Recommendations—beneﬁts and risks of T therapy
Beyond 6 mo there is evidence of beneﬁt for T therapy in body composition, bone mineralization, and
features of metabolic syndrome.
3 A
T therapy improves sexual desire, erectile function, and sexual satisfaction 1 A
Decreases in BMI and waist size and improved glycemic control and lipid proﬁle are observed in
hypogonadal men receiving T therapy
2 A
Trials of T therapy should be 6 mo and maximal beneﬁt is often seen beyond 12 mo 2 A
Fully inform the patient about expected beneﬁts and side effects of therapy and facilitate a joint decision by
an informed patient and physician
3 A
Fully discuss the adverse effect of T therapy and its future reversibility on future fertility for each patient
and his partner and offer alternative treatment as necessary
1b B
In patients with adult-onset TD, when TRT is prescribed, offer weight-loss and lifestyle advice as standard
management
2 A
In severely symptomatic patients with TT levels < 8 nmol/L, lifestyle and dietary advice alone is unlikely to
produce meaningful clinical improvement within a relevant clinical period
2 B
Recommendations—follow-up
Assess response to therapy at 3, 6, and 12 mo and every 12 mo thereafter 4 C
Aim for a target TT level of 15e30 nmol/L to achieve optimal response 4 C
Monitor hematocrit before treatment, at 3e6 mo, 12 mo, and every 12 mo thereafter; decrease dosage, or
switch preparation, if hematocrit is >0.54; if hematocrit remains high, consider stopping and reintroduce
at a lower dose
4 C
Assess prostate health by PSA and DRE before commencing TRT followed by PSA at 3e6 mo, 12 mo, and
every 12 mo thereafter
4 C
Assess cardiovascular risk before TRT is initiated and monitor cardiovascular risk factors throughout
therapy
1b A
BMI ¼ body mass index; DRE ¼ digital rectal examination; ED ¼ erectile dysfunction; LH ¼ luteinizing hormone; LoE ¼ level of evidence; PSA ¼ prostate-
speciﬁc antigen; T ¼ testosterone; TD ¼ testosterone deﬁciency; TRT ¼ testosterone replacement therapy; TT ¼ total testosterone.
BSSM Guidelines on Adult Testosterone Deﬁciency 1515no justiﬁcation for selecting one system over another except for
patient choice.
The BSSM recommends initiating T therapy only in men
with bothersome symptoms (Table 4), in conjunction with
weight-loss advice, lifestyle modiﬁcation, and treatment of
comorbidities (LoE ¼ 2, Grade ¼ A). Weight loss and lifestyleJ Sex Med 2017;14:1504e1523modiﬁcation alone have failed to demonstrate effective
improvement in clinical symptoms, even after more than 4 years,
and patients need to be informed of this.41,42,128
For sexual dysfunction, a patient’s desire to achieve a satis-
factory sexual response is a major driver for T therapy in isolation
or with erectogenic therapy.5 Men with documented TD and
1516 Hackett et alpoor morning erections, ED, and/or decreased libido are candi-
dates for T therapy.26
T therapy is appropriate for treating ED, particularly at TT levels
lower than 8 nmol/L5,7 or calculated FT levels lower than 225 pmol/
L and for salvaging ED treatment failures with oral medication,
particularly at TT levels lower than 10.4 nmol/L.47 Furthermore,
appropriate intervention with T therapy lessens the need for more
invasive second- and third-line treatments in these patients.129
Although these indications for T therapy are often considered
vitally important to the patient, they could be considered of low
importance by the physician not specializing in sexual dysfunction.
Because sexual dysfunction is oftenmultifaceted in nature, involving
physical, behavioral, psychological, interpersonal, and contextual
aspects,130 psychosexual therapy also might be indicated.1
A combination of T and PDE5i treatment should be
considered in patients with TD and ED who do not respond to
either treatment in isolation, especially in those with multiple
risk factors for ED in addition to TD (LoE ¼ 2, Grade ¼ A).
In men with T2DM, improvements in symptoms appear to
parallel improvements in T levels.51
Although TD is often associated with decreased fertility,
treatment with exogenous T decreases endogenous T production
through negative feedback in the hypothalamic-pituitary-gonadal
axis,4 resulting in decreased LH and FSH levels and decreased
spermatogenesis. If a man wishes to father children in the near
future, then the risk of T therapy on fertility needs to be dis-
cussed, because long-term use is associated with azoospermia. A
wish for paternity is one of the main contraindications to T
therapy.4 For secondary TD, possible alternatives include human
chorionic gonadotropin, selective estrogen receptor modulators
(eg, clomiphene), and aromatase inhibitors. Selective estrogen
receptor modulators and aromatase inhibitors are particularly
useful in men with metabolic disturbances. However, these drugs
should not be used when pituitary function is compromised.
There is no scientiﬁc basis for withholding T therapy from
men with TD based on age.1
The clinical and physiologic responses to T therapy, particu-
larly the beneﬁts of increased muscle mass and strength,54 might
be more clinically and economically signiﬁcant in older men,
because decreased muscle mass and lower limb strength are
strongly related to frailty and an increased rate of falls.131
Recent research has suggested a greater decrease in all-cause
mortality in men older than 75 years treated with T.84 The
traditional view that younger men experience greater beneﬁt
from improvement in sexual symptoms associated with T therapy
has not been supported by recent studies.132
When T therapy is used in men with benign prostatic hyper-
plasia, symptomatic improvement of LUTS has been reported.6
The clinical response to T therapy appears unrelated to the
underlying etiology,133 because recent studies have shown
beneﬁts in men without “classic TD” and because such“textbook” conditions are relatively uncommon in the general
population. It is really a matter of clinical judgement and pa-
tient expectation as to whether the underlying conditions
should be addressed ﬁrst,1 but because many men with TD are
sick and/or obese, evidence suggests that better outcomes can be
achieved if lifestyle modiﬁcations, including weight loss, and T
therapy are combined.4,38
It seems that responsiveness to T therapy is dependent not
only on serum T concentration but also on the length of CAG
repeats on the AR. Longer CAG repeats are associated with more
severe symptoms and decreased response to standard-dose ther-
apy. The wide variations in CAG repeats within different ethnic
groups is particularly important in the ethnically diverse UK
population.25,134
For treatment duration, in 2 RCTs involving 447 men 45 to
90 years old, cessation of T therapy resulted in relapse and
reversal of beneﬁts within 6 months, so it is likely to be required
life long.47,135ADVERSE EFFECTS OF T THERAPY
Serious adverse events related to T therapy are relatively rare.
They are more signiﬁcant in elderly patients and often depen-
dent on the method of delivery. Some adverse events are related
to supraphysiologic levels and can be lowered or stopped alto-
gether by adjusting the dose or switching to a different
formulation.6
Intramuscular injections are associated with pain at the in-
jection site, changes in mood, energy, and sexual desire, and,
rarely, coughing straight after the injection.1
Transdermal gels carry a risk of interpersonal transfer, skin
irritation, and ﬂuctuations in absorption.1
The 17a-alkylated formulations are associated with a risk of
hepatotoxicity, cholestasis, peliosis hepatis, hepatic tumors, and a
marked decrease in high-density lipoprotein cholesterol.1 These
treatments should no longer be prescribed.5
Other side effects seen with T therapy include polycythemia
(which is more common in older men treated with injectable T
preparations),5 with increases in hematocrit and hemoglobin,
gynecomastia, edema, acne, and other skin reactions.1
Obese men are more likely to develop adverse effects from T
therapy than men of normal weight.5CONTRAINDICATIONS TO T THERAPY
The main contraindications to T therapy are4:
 Locally advanced or metastatic pCa
 Male breast cancer
 An active desire to have children
 Hematocrit higher than 54%
 Severe chronic heart failure (New York Heart Association
class IV)J Sex Med 2017;14:1504e1523
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nodule or induration, PSA level higher than 4 ng/mL6,22 (or >3
ng/mL in men at high risk of pCa, such as African Americans
and those with ﬁrst-degree relatives who have pCa),22 severe,
untreated sleep apnea,26 and severe LUTS associated with benign
prostatic hyperplasia as indicated by the American Urological
Association symptom index and International Prostate Symptom
Score higher than 19.6,22
A critical update of the ES guidelines published in 2015,136
which examined the body of level 1 evidence literature pub-
lished since 2010, stated that patients with increased PSA
levels should be referred for urologic consultation before
initiating T replacement therapy, and untreated sleep apnea
and severe LUTS might not be absolute contraindications to
T therapy.Recommendations—beneﬁts and risks of T therapy LoE Grade
Beyond 6 mo there is evidence of beneﬁt
for T therapy in body composition, bone
mineralization, and features of metabolic
syndrome
3 A
T therapy improves sexual desire, erectile
function, and sexual satisfaction
1 A
Decreases in BMI and waist size and improved
glycemic control and lipid proﬁle are observed
in hypogonadal men receiving T therapy
2 A
Trials of T therapy should be 6 mo and
maximal beneﬁt is often seen beyond 12 mo
2 A
Fully inform the patient about expected
beneﬁts and side effects of therapy and
facilitate a joint decision by an informed
patient and physician
3 A
Fully discuss the adverse effect of T therapy
and its future reversibility on future fertility
for each patient and his partner and offer
alternative treatment as necessary
1b B
In patients with adult-onset TD, when
T replacement therapy is prescribed, offer
weight-loss and lifestyle advice as standard
management
2 A
In severely symptomatic patients with
TT levels < 8 nmol/L, lifestyle and dietary
advice alone is unlikely to produce meaningful
clinical improvement within a relevant
clinical period
2 BFOLLOW-UP AND MONITORING
Before initiating T therapy, hematologic assessment should be
performed, prostate health should be assessed by DRE and PSA,
the man’s breasts should be checked, CV risk factors should be
assessed, and men with CVD should receive evaluation of CV
symptoms and optimization of secondary prevention.4
After initiation of T therapy, we recommend evaluating pa-
tients at 3, 6 and 12 months and then every 12 monthsJ Sex Med 2017;14:1504e1523thereafter to assess serum T levels, conﬁrm symptomatic
improvement, and check for any changes in hematocrit, PSA
level, and DRE results. Follow-up every 3 months might be
necessary in some patients, including those with a suboptimal
treatment response or safety issues, such as a high or increasing
hematocrit or PSA levels.6
Monitoring levels of TT, SHBG, and albumin (to calcu-
late bioavailable or FT) is required to ensure normal T levels
are being achieved. Currently, there are insufﬁcient data to
deﬁne optimal serum T levels during treatment. The aim of
therapy is to restore serum T levels to the mid-normal range
for speciﬁc age groups.4 Impairment of sexual function and
nocturnal erections are usually associated with TT levels
lower than 7 nmol/L, with the maximal beneﬁt of T
appearing to result with levels of at least 12 to 16 nmol/
L.6,137
For monitoring purposes, we recommend a therapeutic
target in the mid to upper range (15e30 nmol/L), making
reference ranges of little value. For patients on transdermal
preparations, blood samples should be taken 2 to 4 hours
after application of gel or lotion, being careful to avoid any
skin contamination. For injections, the timing for blood
testing is irrelevant, because the trough levels, which assess
the duration of effect of the formulation, are all that are
required.
Hematocrit levels should remain below 54%4,6,26 (LoE ¼ 2,
Grade ¼ B).6 Dose adjustments and/or periodic venesection
might be required to achieve this.5
PSA increases greater than 1.4 ng/mL during any 1-year
period after initiation of T therapy or a PSA velocity greater
than 0.4 ng/mL per year during sequential PSA measurements
over more than 2 years warrant a urologic evaluation and more
intensive surveillance for pCa thereafter.5
Men with CVD should be monitored carefully, with clinical
assessment and measurement of T and hematocrit performed
regularly.4
Bone mineral density should be monitored only in men with
abnormal bone mineral density before initiating T therapy,4,6
and repeat dual energy x-ray absorptiometry is recommended
after 1 to 2 years of T therapy.6
Although monitoring of serum lipids and glycemia is not
required for safety during T therapy, it could be necessary for
monitoring the efﬁcacy of other aspects of treatment (LoE ¼ 2,
Grade ¼ A).6
Assessment of treatment outcome and decisions regarding
continuation of T therapy should be based on improvement in
signs and symptoms of TD. Failure to beneﬁt within a reasonable
timeframe (deﬁned as 6 months for libido, sexual function,
muscle function, and improved body fat) should prompt
discontinuation of treatment. Further investigation for other
causes of the symptoms is essential.5
Recommendations—follow-up LoE Grade
Assess the response to therapy at 3, 6, and
12 mo and every 12 mo thereafter
4 C
Aim for a target TT level of 15e30 nmol/L
to achieve optimal response
4 C
Monitor hematocrit before treatment, at
3e6 mo, 12 mo, and every 12 mo thereafter;
decrease dosage, or switch preparation,
if hematocrit is >0.54; if hematocrit remains
high, consider stopping and reintroduce at
lower dose
4 C
Assess prostate health by PSA assessment
and DRE before commencing T replacement
therapy followed by PSA at 3e6 mo, 12 mo,
and every 12 mo thereafter
4 C
Assess CV risk before T replacement therapy
is initiated and monitor CV risk factors
throughout therapy
1b A
1518 Hackett et alCONCLUSION
TD is a well-established and signiﬁcant medical condition,
encompassing somatic, sexual, and psychological effects. It also is
associated with increased CV and all-cause mortality. Clearly
deﬁned clinical symptoms should prompt swift evaluation of
these and the underlying risk factors, and further investigations
should be performed when appropriate.
To identify individuals who should be screened for TD,
consideration should be given to routinely asking men if they
have any sexual concerns, particularly those at high risk. These
include men with diabetes, osteoporosis or fragility fractures,
CVD, ED, and depression and those on long-term opiate or oral
glucocorticoid therapy.
T therapy is based on evidence, effective, and safe, and
treatment-related sustained normalization of serum T levels is
probably associated with lower mortality.
However, although the multiple beneﬁts of T therapy are
highly relevant to the patient, they are often underestimated by
specialist physicians focused on speciﬁc outcomes. Because sexual
dysfunction is often multifaceted in nature, the treatment of men
with sexual desire, arousal, and ejaculation problems should be
individualized and can include T therapy, erectogenic agents, and
psychosexual therapy.
Until a deﬁnitive well-powered long-term study is published,
treatment of TD with T therapy should be guided by the best
available evidence.
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